PROTAC Light Chain Degraders for Amyloidosis Organ Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for light chain amyloidosis, such as chemotherapy and stem cell transplants, achieve incomplete eradication of clonal plasma cells and often result in poor organ function outcomes, with existing response criteria failing to account for residual light chain levels that can cause organ dysfunction.
Innovation Solution
Development of PROTAC compounds that target immunoglobulin light chains, utilizing E3 ligase ligands or N-degron pathway activators to degrade or stabilize light chains, thereby preventing misfolding and endoproteolysis, and potentially used in combination therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy and stem cell transplants are used to treat light chain amyloidosis, then clonal plasma cells are eradicated to some extent, but complete eradication is not achieved and organ function outcomes remain poor
Solution Approach 1:
The invention extracts and targets the specific problem of residual light chains that cause organ dysfunction. By developing response criteria that specifically measure light chain levels rather than just plasma cell burden, the treatment approach can be optimized to address the actual cause of organ damage, separating the evaluation of plasma cell eradication from organ function recovery
Solution Approach 2:
The invention changes the measurement parameter from plasma cell count to light chain level assessment. This parameter change enables more accurate monitoring of treatment effectiveness regarding organ function, as light chain levels directly correlate with organ toxicity rather than plasma cell burden
2Difficulty of detecting and measuring
If current response criteria are used to assess treatment, then plasma cell burden is measured, but residual light chain levels causing organ dysfunction are not detected
Solution Approach 1:
The invention substitutes the mechanical/cellular assessment method (counting plasma cells) with a biochemical measurement method (quantifying light chain levels). This substitution provides more precise measurement of the actual toxic agent (light chains) rather than the source cells, enabling better correlation with organ function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PROTAC compounds effectively degrade or stabilize immunoglobulin light chains, reducing organ toxicity and improving treatment outcomes by addressing residual light chain issues not covered by current therapies.
Implementation Method 1
PROTACs are believed to induce formation of a ternary complex between the target protein, the PROTAC compound, and an E3 ligase ligand. The PROTAC thus brings the target protein into close proximity to an E3 ligase
Implementation Method 2
The PROTAC thus brings the target protein into close proximity to an E3 ligase, which leads to (poly)ubiquitination of the surface of the target protein making it a neosubstrate for proteosomal degradation
Implementation Method 3
the compounds are stabilizers of immunoglobulin light chains... the immunoglobulin light chains are stabilized in a native conformation thereof... preventing misfolding and endoproteolysis
Data Source
AI summary
Provided herein are compounds and pharmaceutically acceptable derivatives thereof for use in compositions and methods of treating light chain amyloidosis. Also provided are methods of degrading immunoglobulin light chains using the compounds and compositions provided herein.